acetylcysteine has been researched along with Glycogen Storage Disease Type II in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourne, Y; Cobucci-Ponzano, B; Ferrara, MC; Germany, S; Iacono, R; Moracci, M; Parenti, G; Roig-Zamboni, V; Sulzenbacher, G | 1 |
| Beller, M; Giese, AK; Gläser, A; Lukas, J; Pockrandt, AM; Pohlers, S; Rolfs, A; Runge, F; Seemann, S; Sharif, M; Zheng, C | 1 |
| Acampora, E; Andria, G; Avolio, V; Cobucci-Ponzano, B; Colombo, G; Ferrara, MC; Meli, M; Moracci, M; Parenti, G; Porto, C; Rosa, M | 1 |
3 other study(ies) available for acetylcysteine and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease.
Topics: Acetylcysteine; alpha-Glucosidases; Catalytic Domain; Glycogen Storage Disease Type II; Humans; Lysosomes; Models, Molecular; Protein Conformation | 2017 |
Enzyme enhancers for the treatment of Fabry and Pompe disease.
Topics: 1-Deoxynojirimycin; Acetylcysteine; alpha-Galactosidase; alpha-Glucosidases; Ambroxol; Bezafibrate; Enzyme Activators; Fabry Disease; Gene Expression; Glycogen Storage Disease Type II; HEK293 Cells; Humans; Leupeptins; Lysosomes; Pioglitazone; Plasmids; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Recombinant Proteins; Thiazolidinediones; Transfection | 2015 |
Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.
Topics: Acetylcysteine; alpha-Glucosidases; Animals; Blotting, Western; Chlorocebus aethiops; COS Cells; Enzyme Stability; Fibroblasts; Fluorescent Antibody Technique; Glycogen Storage Disease Type II; Humans; Mice; Microscopy, Confocal; Molecular Chaperones | 2012 |